YishengBio Raises $130 Million for Immunomodulating Therapies

Beijing 's YishengBio closed a $130 million Series B funding round to develop novel biotherapeutics for cancer and infectious diseases using its novel PIKA® immunomodulating technology. The company's YSJA™ rabies vaccine is the first alum-free lyophilized rabies vaccine launched in China . Its novel PIKA immunomodulating technology platform increases innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. The B round was co-led by Oceanpine and OrbiMed. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.